



## **NanoSphere Health Sciences Announces Patent-Pending Status for Nanoparticle Encapsulation of Cannabinoids**

### **Advanced Nanobiotechnology Enables Standardized Dosages, Increased Bioavailability and Improved Efficacy of Cannabis Therapy**

**DENVER – June 10, 2015 – [NanoSphere Health Sciences, LLC](#)**, innovative developers of the industry-first, patent-pending [NanoSphere™](#) delivery system, announced today that the U.S. Patent and Trademark office issued “Patent Pending” status for its new cannabis NanoSphere technology platform.

NanoSphere Health Sciences is the first and only patent-pending nanoparticle delivery system for medical and recreational cannabis. Concentrated “NanoSpheres” deliver plant extracts of cannabis and purified cannabinoids in convenient, standardized dosages to increase bioavailability, bioactivity and therapeutic potential. At the same time, the natural phospholipid particles decrease the adverse effects of cannabis.

Cannabinoids have a very low absorption rate when taken orally, combined with the fact that marijuana taken in edible form can take 40 minutes to one hour to start working. The significant delay in action can lead to problems, such as accidental over-administration or “stacking.”

NanoSphere Health is scientifically formulated to be directly absorbed through the bloodstream, targeting cells for higher potency and rapid onset of actions. This results in increased effectiveness due to reduced dose and frequency of administration.

“While significant advancements and investments have been made in the medical cannabis industry, we are the first to apply nanotechnology to improve the bioavailability and efficacy of cannabis extracts and standardized dosages,” said Dr. Richard Kaufman, Chief Science Officer at NanoSphere Health Sciences. “This disruptive technology introduces a significant advancement in the medical and recreational cannabis markets, and meets the regulatory demands for product purity, uniformity and the reporting of active cannabinoid levels.”

The NanoSphere Delivery System revolutionizes how cannabis delivers its benefits. Liquid NanoSpheres nanosize, encapsulate and rapidly deliver concentrated plant extracts and cannabis, purified cannabinoids, with increased bioavailability, bioactivity and therapeutic potential in standardized dosages printed on the product labels. At the same time, the biocompatible, phospholipid nanoparticles spheres (less than 70 nm in diameter) help decrease the adverse effects of cannabinoids.

NanoSphere's cannabinoid products are uniquely designed to be administered intra-orally, intra-nasally and transdermally in precision dose-metered dispensers. The convenient-to-use liquid NanoGels bypass the GI tract and avoid 1st pass liver metabolism. NanoSphere offers the ultimate in convenience, ease-of-use and safety.

The company's patent-pending NanoSphere phospholipid nanoparticle encapsulation of cannabinoids provides practical solutions for cannabinoid therapy with benefits of:

- Standardized Dose-Metered Dosages
- Higher Concentration of CBD and THC
- Increased Bioavailability
- Decreased Dosages
- Decreased Adverse Effects
- Decreased Tolerance to Cannabis from Prolonged Use
- More Efficacious Cannabinoid Therapy and Medical Cannabis Treatments
- Enhanced Therapeutic Value
- Ideal for Long-Term and Daily Use
- Easy to use and Safe

NanoSphere Health's business model integrates into the regulatory and product manufacturing chain-of-possession. NanoSphere is partnering with cannabis growers, extractors, product manufacturers and dispensaries in providing this revolutionary product. The NanoSphere Delivery System satisfies the regulatory requirements for quality control, standardized cannabis dosages, full disclosure labeling and complete transparency.

### **About NanoSphere Health Sciences, LLC**

Headquartered in Denver, Colorado, NanoSphere Health Sciences is a biotechnology firm specializing in the creation of NanoSphere™ delivery system platforms for the supplement, nutraceutical, OTC, pharmaceutical, cannabis industries and beyond. Its patent-pending NanoSphere delivery systems represent one of the most important developments for advancing the non-invasive delivery of biological agents in over 25 years.  
[www.nanospherehealth.com](http://www.nanospherehealth.com).

###

#### **PR Contact:**

Cannabrand

Olivia Mannix

CMO/Co-Founder

**Direct:** 303.223.7411

**Mobile:** 203.858.6997

**E-mail:** [olivia@cannabrand.us](mailto:olivia@cannabrand.us)